Scott A. Hammond

6.2k total citations · 2 hit papers
82 papers, 3.8k citations indexed

About

Scott A. Hammond is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Scott A. Hammond has authored 82 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Immunology, 36 papers in Oncology and 22 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Scott A. Hammond's work include Immunotherapy and Immune Responses (30 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Immune Cell Function and Interaction (24 papers). Scott A. Hammond is often cited by papers focused on Immunotherapy and Immune Responses (30 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Immune Cell Function and Interaction (24 papers). Scott A. Hammond collaborates with scholars based in United States, France and United Kingdom. Scott A. Hammond's co-authors include Gregory M. Glenn, Ronald C. Montelaro, Robert F. Siliciano, Marie‐Caroline Dieu‐Nosjean, Diane Damotte, Larry Ellingsworth, Jérémy Goc, Sheila J. Cook, Catherine Sautès‐Fridman and Wolf H. Fridman and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Scott A. Hammond

74 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells

2013 500 citations Jérémy Goc, Claire Germain et al. Cancer Research profile →
Androgen receptor activity in T cells limits checkpoint blockade efficacy

2022 233 citations Scott A. Hammond et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Scott A. Hammond	2.1k	1.7k	753	521	465	82	3.8k
Jean‐Pierre Abastado	3.1k 1.5×	1.3k 0.8×	1.3k 1.7×	340 0.7×	572 1.2×	95	4.8k
Rafael Cubas	2.4k 1.1×	1.1k 0.7×	688 0.9×	149 0.3×	382 0.8×	42	3.6k
Francisco Borrás‐Cuesta	1.4k 0.7×	627 0.4×	1.2k 1.5×	417 0.8×	644 1.4×	88	3.4k
Jos Even	3.2k 1.5×	1.3k 0.8×	903 1.2×	529 1.0×	518 1.1×	73	4.5k
Josef Cihak	1.9k 0.9×	663 0.4×	900 1.2×	281 0.5×	293 0.6×	44	3.1k
Bernard Maillère	1.8k 0.9×	601 0.4×	1.2k 1.6×	631 1.2×	437 0.9×	141	3.7k
Jean‐François Fonteneau	2.7k 1.3×	980 0.6×	1.1k 1.5×	118 0.2×	530 1.1×	75	3.7k
Kazuhiro Kakimi	3.6k 1.7×	2.3k 1.4×	997 1.3×	245 0.5×	1.2k 2.5×	160	5.6k
Béatrice Vanbervliet	7.1k 3.4×	1.6k 1.0×	1.4k 1.8×	469 0.9×	561 1.2×	47	8.4k
Alice J.A.M. Sijts	2.5k 1.2×	958 0.6×	2.2k 2.9×	248 0.5×	615 1.3×	83	4.3k

Countries citing papers authored by Scott A. Hammond

Since Specialization

Citations

This map shows the geographic impact of Scott A. Hammond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Hammond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Hammond more than expected).

Fields of papers citing papers by Scott A. Hammond

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Hammond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Hammond. The network helps show where Scott A. Hammond may publish in the future.

Co-authorship network of co-authors of Scott A. Hammond

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Hammond. A scholar is included among the top collaborators of Scott A. Hammond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Hammond. Scott A. Hammond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Colin Y.C., Isaac Dean, Nathan Richoz, et al.. (2025). In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade. Cancer Immunology Research. 13(9). 1453–1470.

Jenkins, Liam, et al.. (2024). Abstract 1366: Dual immune checkpoint inhibition enhances the anti-tumor activity of trastuzumab deruxtecan in preclinical models. Cancer Research. 84(6_Supplement). 1366–1366.

Hammond, Scott A., et al.. (2024). Artificial intelligence algorithm accurately assesses oestrogen receptor immunohistochemistry in metastatic breast cancer cytology specimens: A pilot study. Cytopathology. 35(4). 464–472. 1 indexed citations

Shilo, Konstantin, Ashwini Esnakula, Saba Shafi, et al.. (2023). Comparison of four different displays for identification of select pathologic features extracted from whole slide images of surgical pathology cases. Pathology - Research and Practice. 251. 154843–154843. 1 indexed citations

Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719. 19 indexed citations

Li, Zhi, Zewen Kelvin Tuong, Isaac Dean, et al.. (2022). In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. The Journal of Experimental Medicine. 219(6). 63 indexed citations

Malhotra, Deepali, Eleanor Clancy‐Thompson, Bilal Omar, et al.. (2022). 469 Preclinical studies support clinical development of AZD2936, a monovalent bispecific humanized antibody targeting PD-1 and TIGIT. Regular and Young Investigator Award Abstracts. A489–A489. 5 indexed citations

Hammond, Scott A., et al.. (2020). A Validation Study of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Digital Imaging Analysis and its Correlation with Human Epidermal Growth Factor Receptor 2 Fluorescence In situ Hybridization Results in Breast Carcinoma. Journal of Pathology Informatics. 11(1). 2–2. 21 indexed citations

Shrimali, Rajeev, Shamim Ahmad, Vivek Verma, et al.. (2017). Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis. Cancer Immunology Research. 5(9). 755–766. 117 indexed citations

10.

Clarke, Neil D., et al.. (2017). Carbohydrate mouth rinse improves morning high‐intensity exercise performance. European Journal of Sport Science. 17(8). 955–963. 24 indexed citations

11.

Oberst, Michael D., Stacy Fuhrmann, Kathy Mulgrew, et al.. (2014). CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. mAbs. 6(6). 1571–1584. 71 indexed citations

12.

Goc, Jérémy, Claire Germain, Thi Kim Duy Vo-Bourgais, et al.. (2013). Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells. Cancer Research. 74(3). 705–715. 500 indexed citations breakdown →

13.

Mulgrew, Kathy, David J. Stewart, Wendy L. Trigona, et al.. (2008). Bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3-specific BiTE antibody MEDI-538 (MT103) delivered subcutaneously in animal models. Cancer Research. 68. 2131–2131. 2 indexed citations

14.

Hammond, Scott A., Ralf Lutterbuese, Shannon Roff, et al.. (2007). Selective Targeting and Potent Control of Tumor Growth Using an EphA2/CD3-Bispecific Single-Chain Antibody Construct. Cancer Research. 67(8). 3927–3935. 66 indexed citations

15.

Belyakov, Igor M., Scott A. Hammond, Jeffrey D. Ahlers, Gregory M. Glenn, & Jay A. Berzofsky. (2004). Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. Journal of Clinical Investigation. 113(7). 998–1007. 7 indexed citations

16.

Hammond, Scott A., Sheila J. Cook, Louis D. Falo, Charles J. Issel, & Ronald C. Montelaro. (1999). A Particulate Viral Protein Vaccine Reduces Viral Load and Delays Progression to Disease in Immunized Ponies Challenged with Equine Infectious Anemia Virus. Virology. 254(1). 37–49. 26 indexed citations

17.

Hammond, Scott A., et al.. (1999). Evaluation of Antibody Parameters as Potential Correlates of Protection or Enhancement by Experimental Vaccines to Equine Infectious Anemia Virus. Virology. 262(2). 416–430. 32 indexed citations

18.

Bollinger, Robert C., Thomas C. Quinn, Alice Y.‐C. Liu, et al.. (1993). Cytokines from Vaccine-Induced HIV-1 Specific Cytotoxic T Lymphocytes: Effects on Viral Replication. AIDS Research and Human Retroviruses. 9(11). 1067–1077. 20 indexed citations

19.

Siliciano, Robert F., Robert C. Bollinger, Scott A. Hammond, et al.. (1992). Clonal Analysis of T-Cell Responses to the HIV-1 Envelope Proteins in AIDS Vaccine Recipients. AIDS Research and Human Retroviruses. 8(8). 1349–1352. 9 indexed citations

20.

Hammond, Scott A., Robert C. Bollinger, P E Stanhope, et al.. (1992). Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.. The Journal of Experimental Medicine. 176(6). 1531–1542. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact